It has been observed that concentrations of CD133+ CD326- EVs decrease when lung cancer patients respond to anticancer therapy (Brocco et al., 2019), and lower levels of circulating CD133+ CD336- EVs in peripheral blood from lung cancer patients are associated with longer survival times compared with patients with higher levels (Brocco et al., 2019). Here, EPCAM is linked to lung cancer.